TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23400204

Group type: EXPERIMENTAL
Intervention: Integrated suction blade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional videolaryngoscope blade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated video suction blade
Number of subjects: 0
Study: 20842417

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine and Western medicine (TCM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional Western medicine treatment (WM)
Number of subjects: 23
Study: 19123718

Group type: EXPERIMENTAL
Intervention: SmartClip
Number of subjects: 66

Group type: COMPARATOR
Intervention: Victory
Number of subjects: 66
Study: 17920550

Group type: EXPERIMENTAL
Intervention: Statins (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins in combination with existing agents for multiple sclerosis therapy
Number of subjects: 0
Study: 15526250

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11457465

Group type: EXPERIMENTAL
Intervention: HN-11 500 (1, 10, 100, 200, and 400 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HN-11 500 (400 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HN-11 500 (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HN-11 500
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9670182

Group type: EXPERIMENTAL
Intervention: Internal cardioversion using low energy biphasic DC shocks via electrodes in the right atrial appendage and coronary sinus.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Signal-averaged P wave (SAPW) analysis at 3 and 24 hours post-cardioversion.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fall in P40 of > 25%.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Signal-averaged P wave (SAPW) analysis after cardioversion.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Patients with relapsing permanent AF remaining in sinus rhythm for at least 1 week after cardioversion.
Number of subjects: 31
Study: 7870008

Group type: EXPERIMENTAL
Intervention: Never treated with chemoantibiotics
Number of subjects: 6
Study: 2693994

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 349324

Group type: EXPERIMENTAL
Intervention: Hexoprenaline sulphate (1 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31407629

Group type: EXPERIMENTAL
Intervention: TPOAb-positive women
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: T4 treatment
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: TPOAb-positive women receiving T4
Number of subjects: 825

Group type: COMPARATOR
Intervention: TPOAb-negative women
Number of subjects: 825
Study: 28438447

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 108
Study: 25275341

Group type: COMPARATOR
Intervention: Enzyme combination (XB)
Number of subjects: 192

Group type: COMPARATOR
Intervention: All additives (EO, XB, EO+XB)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Essential oils (EO)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Essential oils + enzyme combination (EO+XB)
Number of subjects: 192
Study: 22696139

Group type: EXPERIMENTAL
Intervention: Ballot box survey method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized response survey method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face survey method
Number of subjects: 0
Study: 22729296

Group type: EXPERIMENTAL
Intervention: Maltodextrin at 12.5% (400 ml 6 hours before and 200 ml 2 hours before)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 40
Study: 20667838

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (TFU)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 17978033

Group type: EXPERIMENTAL
Intervention: Placebo administered after precompetition training with morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine administered during precompetition training
Number of subjects: 0
Study: 15726333

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0, 8, 16, and 32 mg per 70 kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 8
Study: 12192632

Group type: COMPARATOR
Intervention: Physician-supervised smoking cessation program with nicotine replacement and brief intervention; Group A (no stress reduction)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Physician-supervised smoking cessation program with nicotine replacement, brief intervention, and 20-hour stress reduction program over 8 weeks; Group B
Number of subjects: 140
Study: 9432177

Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 71
Study: 8088113

Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary advice
Number of subjects: 51
Study: 2783530

Group type: EXPERIMENTAL
Intervention: Umbilical vein oxytocin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 50
Study: 15903

Group type: EXPERIMENTAL
Intervention: Intraamniotic prostaglandin F2alpha (50 mg single dose)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intraamniotic prostaglandin F2alpha (25 mg repeated dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraamniotic hypertonic saline
Number of subjects: 50
Study: 31653353

Group type: EXPERIMENTAL
Intervention: Thienopyridine interruption
Number of subjects: 23002
Study: 28097268

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 189

Group type: COMPARATOR
Intervention: Rigid cystoscopy
Number of subjects: 189
Study: 26312582

Group type: EXPERIMENTAL
Intervention: Interrupted sitting (3 min of moderate-intensity walking every 30 min)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous sitting
Number of subjects: 28
Study: 22572805

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21848797

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 219
Study: 19332204

Group type: EXPERIMENTAL
Intervention: Transradial PCI with maximal antiplatelet therapy (aspirin and clopidogrel, 70 U/kg heparin, abciximab before first balloon inflation)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1348
Study: 16494145

Group type: EXPERIMENTAL
Intervention: Continuous 3‐in‐1 femoral nerve catheter with 0.15% ropivacaine (Group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Continuous 3‐in‐1 femoral nerve catheter with 0.2% ropivacaine (Group B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Patient controlled intravenous morphine (Group C - control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Comparison of groups A and B
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 55
Study: 12934417

Group type: EXPERIMENTAL
Intervention: Closed-circuit anesthesia (CCA)
Number of subjects: 50
Study: 11104393

Group type: EXPERIMENTAL
Intervention: Covariate analysis adjusted for center effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted squares of means analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual maximum likelihood (REML) estimation
Number of subjects: 0
Study: 9244901

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) in lateral lying position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Impulse oscillometry (IOS) in sitting position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) measurements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) in lying position
Number of subjects: 20
Study: 8445231

Group type: EXPERIMENTAL
Intervention: Oral pulse prednisone therapy (90 mg daily for 5 days each month)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional daily dose therapy with prednisone in combination with azathioprine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral pulse prednisone therapy
Number of subjects: 16
Study: 3524066

Group type: EXPERIMENTAL
Intervention: MDL 646, 400 micrograms q.i.d.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MDL 646, 800 micrograms q.i.d.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Indomethacin, 50 mg t.i.d. for 6 days
Number of subjects: 7
Study: 30541530

Group type: EXPERIMENTAL
Intervention: Exercise program and Nurse Home visit and Telephone follow‐up (ExN‐HaT)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Nurse Home visit and Telephone follow‐up (N‐HaT)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 222

Group type: COMPARATOR
Intervention: Exercise program only
Number of subjects: 222
Study: 27139431

Group type: EXPERIMENTAL
Intervention: Psoriasis vulgaris patients
Number of subjects: 100
Study: 24481415

Group type: EXPERIMENTAL
Intervention: Prophylactic normothermia group with a target core temperature of 36.5°C using endovascular cooling
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional stepwise predefined fever management using antipyretic medication and surface cooling (Control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (Endovascular and Control)
Number of subjects: 46
Study: 22751270

Group type: EXPERIMENTAL
Intervention: Integrated treatment combining medical-nutritional interventions and family psychotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual medical-nutritional intervention supported by psychiatric counselling
Number of subjects: 28
Study: 20581776

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Saline (2 mL)
Number of subjects: 160
Study: 17343310

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 0
Study: 16295646

Group type: EXPERIMENTAL
Intervention: High communication performance
Number of subjects: 179

Group type: COMPARATOR
Intervention: Adequate communication performance
Number of subjects: 179

Group type: COMPARATOR
Intervention: Casual, business casual, formal dress styles and white coat (wearing or not)
Number of subjects: 179
Study: 11814498

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg)
Number of subjects: 109

Group type: COMPARATOR
Intervention: PGE2 (2.5 mg)
Number of subjects: 109
Study: 10364702

Group type: EXPERIMENTAL
Intervention: Exercise coaching and rehabilitation counseling (R) for 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sickness impact profile scores in PR
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Comorbidity correlations
Number of subjects: 36
Study: 7591118

Group type: EXPERIMENTAL
Intervention: Norwegian group B meningococcal OMV vaccine (3 doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Norwegian group B meningococcal OMV vaccine (2 doses)
Number of subjects: 27
Study: 2186023

Group type: EXPERIMENTAL
Intervention: Clonazepam treatment group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nontreatment control group
Number of subjects: 23
Study: 368045

Group type: EXPERIMENTAL
Intervention: Penfluridol (once weekly)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Chlorpromazine (once daily)
Number of subjects: 56
Study: 31814312

Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT) during the continuation phase of anti-TB therapy
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) change during anti-TB treatment
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: CD4+ count at TB diagnosis
Number of subjects: 1862
Study: 28418209

Group type: EXPERIMENTAL
Intervention: Acupressure band at the Neiguan point (P6) for 12 hours daily for three days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupressure band at the Neiguan point (P6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo wristband (non‐stimulating)
Number of subjects: 0
Study: 26978418

Group type: EXPERIMENTAL
Intervention: ARTRA MSM (400 mg chondroitin sulfate, 500 mg glucosamine hydrochloride, 300 mg methylsulfonylmethane (MSM), and 10 mg sodium hyaluronate) taken as 2 tablets daily for one month, then 1 tablet daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: ARTRA (same composition as ARTRA MSM) taken in accordance with the same scheme
Number of subjects: 100
Study: 24187120

Group type: EXPERIMENTAL
Intervention: Planned Activities Training (PAT)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Cellular Phone-Enhanced Planned Activities Training (CPAT)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: PAT and CPAT
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: CPAT
Number of subjects: 371

Group type: COMPARATOR
Intervention: Wait-List Control (WLC)
Number of subjects: 371
Study: 21421039

Group type: EXPERIMENTAL
Intervention: Vinorelbine-loaded lipid emulsion (VLE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial product, Navelbine(®) i.v. (VS)
Number of subjects: 0
Study: 19393786

Group type: EXPERIMENTAL
Intervention: Roadside Impairment Testing Apparatus (RITA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Field Impairment Tests (FIT)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Horizontal Gaze Nystagmus (HGN)
Number of subjects: 122
Study: 15969860

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study: 12208595

Group type: COMPARATOR
Intervention: Plasma t‐PA concentration on day 1 of acute MI
Number of subjects: 106

Group type: COMPARATOR
Intervention: Plasma PAI‐1 concentration on day 1 of acute MI
Number of subjects: 106

Group type: COMPARATOR
Intervention: Plasma C‐reactive protein concentration on day 1 of acute MI
Number of subjects: 106

Group type: COMPARATOR
Intervention: Plasma t‐PA concentration on day 28 after admission
Number of subjects: 106
Study: 10075054

Group type: EXPERIMENTAL
Intervention: Proinflammatory activity in ARDS fluids
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MMP-2 levels in ARDS edema fluids
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Proinflammatory activity in plasma from ARDS patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Levels of procollagen peptide III in permeability edema fluids
Number of subjects: 31

Group type: COMPARATOR
Intervention: SAPS II and LIS scores in ARDS patients
Number of subjects: 31
Study: 8544139

Group type: EXPERIMENTAL
Intervention: Toe-down rotation of a supporting platform
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toe-up rotation of a supporting platform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stable frame holding condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platform displacement at 140 ms after go-signal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platform displacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition to a new, stabilized postural 'set'
Number of subjects: 0
Study: 1761065

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg b.d. for 1 week
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Verapamil administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7135175

Group type: EXPERIMENTAL
Intervention: choledochoduodenostomy (group A, 40 patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: sphincteroplasty (group B, 40 patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: T-tube drainage (group C, 40 patients)
Number of subjects: 120
Study: 30680768

Group type: COMPARATOR
Intervention: Aflibercept monotherapy (AM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aflibercept plus pranoprofen (AP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aflibercept plus nutraceutical (AN)
Number of subjects: 60
Study: 29269717

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 25683116

Group type: EXPERIMENTAL
Intervention: larazotide acetate 0.5 mg 3 times daily
Number of subjects: 342

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 342
Study: 24804871

Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (250 mg) with 20 mg piperine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (250 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21519222

Group type: EXPERIMENTAL
Intervention: Palonosetron + Dexamethasone (8-mg dexamethasone + 0.075-mg palonosetron)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Palonosetron alone (0.075 mg palonosetron)
Number of subjects: 118
Study: 19242322

Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH) 500 units/hour for 7 days
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH)
Number of subjects: 319
Study: 17237216

Group type: EXPERIMENTAL
Intervention: Obtuse angle approach
Number of subjects: 83

Group type: COMPARATOR
Intervention: Acute angle approach
Number of subjects: 83
Study: 14666114

Group type: EXPERIMENTAL
Intervention: L‐759274 40 mg daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 12146536

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9696260

Group type: EXPERIMENTAL
Intervention: Bioabsorbable membrane (Guidor)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional flap therapy
Number of subjects: 40
Study: 8123509

Group type: EXPERIMENTAL
Intervention: Sterets and Ster-zac powder
Number of subjects: 100

Group type: COMPARATOR
Intervention: Untreated umbilical cords
Number of subjects: 100
Study: 2759945

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, twice daily for 5 days)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 785691

Group type: EXPERIMENTAL
Intervention: Defibrase (snake venom enzyme) administered daily for 3 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 28319018

Group type: EXPERIMENTAL
Intervention: Elevated serum progesterone (≥4.6 nmol/l)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Elevated progesterone level with rise in LH
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (no elevated progesterone)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (no elevated progesterone with rise in LH)
Number of subjects: 271
Study: 26087584

Group type: EXPERIMENTAL
Intervention: Stimulant mesocarb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nootropic and anxiolytic fenibut
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranquilizer fenazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-adrenoblocker proroxan
Number of subjects: 0
Study: 24284358

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET) after percutaneous transluminal angioplasty (PTA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (PTA alone)
Number of subjects: 50
Study: 21533818

Group type: EXPERIMENTAL
Intervention: Eltrombopag (thrombopoietin receptor agonist)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 19292211

Group type: EXPERIMENTAL
Intervention: Bilateral total knee arthroplasty (TKA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bilateral total hip arthroplasty (THA)
Number of subjects: 50
Study: 16243460

Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.30% retinol for 21 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.55% retinyl palmitate for 21 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single oral doses of 10,000 IU retinyl palmitate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single oral doses of 30,000 IU retinyl palmitate
Number of subjects: 14
Study: 12827681

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiation therapy (RT) at 50 Gy in daily fractions of 2 Gy, 5 days/week for 5 weeks
Number of subjects: 218

Group type: COMPARATOR
Intervention: Sequential postoperative RT plus chemotherapy (CT) with 5-FU (450 mg/sqm/day i.v. bolus, days 1-5) and LEV (150 mg/day orally, days 1-3)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiation therapy (RT) alone
Number of subjects: 218

Group type: COMPARATOR
Intervention: Sequential postoperative RT and CT
Number of subjects: 218
Study: 11018607

Group type: EXPERIMENTAL
Intervention: Treatment arm (nifedipine XL, prednisone, trimethoprim/sulfa, plain acetaminophen)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control arm (ketorolac, oxycodone, acetaminophen, prochlorperazine)
Number of subjects: 70
Study: 8898770

Group type: EXPERIMENTAL
Intervention: Community-based heart disease prevention programs
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1396
Study: 1501619

Group type: EXPERIMENTAL
Intervention: Carrot-rice based rehydration solution (Na 57 mmol/L)
Number of subjects: 178

Group type: COMPARATOR
Intervention: High-Na glucose electrolyte solution (Na 90 mmol/L)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Low-Na glucose electrolyte solution (Na 55 mmol/L)
Number of subjects: 178
Study: 6371575

Group type: EXPERIMENTAL
Intervention: Neurotropic drug (3 X 200 mg EMD 21657)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30821053

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo QM
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Evolocumab (both dosing regimens)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Evolocumab and Placebo
Number of subjects: 981